Hypoplastic left heart syndrome, or HLHS, has a historical mortality rate of 20% within five years of diagnosis. The disease affecting children may have a new therapy in Longeveron’s LGVN Lomecel-B. The drug candidate showed a 100% survival rate after 5 years in its ELPIS I trial, according to Longeveron.
The clinical stage biotechnology company develops cellular regenerative therapies that are patient focused and designed to combat a range of age-related diseases. It currently has several trials underway for diseases like HLHS, Alzeimer’s, and Aging Frailty.
Learn more here:
Featured photo by Louis Reed on Unsplash.
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
